Earnings summaries and quarterly performance for KRON.
Research analysts covering KRON.
Recent press releases and 8-K filings for KRON.
Kronos Bio acquired by Concentra Biosciences via merger
KRON
M&A
Delisting/Listing Issues
Board Change
- Kronos Bio completed a tender offer and merger with Concentra Biosciences, LLC, effective June 20, 2025, under which Merger Sub purchased 44,503,838 shares (≈72.9% of outstanding stock) for $0.57 cash per share plus one CVR each.
- Upon closing, Kronos Bio became a wholly owned subsidiary of Concentra with no stockholder vote required under Section 251(h) of the DGCL.
- The company requested Nasdaq to suspend trading and delist its common stock effective before the opening on June 20, 2025, and plans to terminate SEC reporting obligations.
- At the Effective Time, existing Kronos directors and officers resigned, and Merger Sub’s executives—led by CEO Kevin Tang and CFO Michael Hearne—assumed governance of the surviving corporation.
- Kronos Bio’s certificate of incorporation and bylaws were amended and restated in their entirety at closing.
Jun 20, 2025, 12:00 AM
Kronos Bio Terminates Lease and Outlines Cost Savings
KRON
M&A
- Lease Termination Announcement: Kronos Bio entered into an agreement to terminate its office and laboratory lease effective June 30, 2025, with a payment of approximately $22.5 million and the return of a $2.0 million security deposit, resulting in an estimated $18.2 million cost saving.
- Offer and Transaction Details: The report also references the tender offer and related merger transactions, with forward-looking statements concerning the timing, conditions, and potential shareholder benefits.
Jun 5, 2025, 12:00 AM
Kronos Bio to Be Acquired by Concentra Biosciences
KRON
M&A
- Kronos Bio will be acquired by Concentra Biosciences for $0.57 in cash per share plus one contingent value right, providing potential future payments tied to product candidate dispositions.
- The acquisition is approved by the Kronos Bio Board, with a tender offer scheduled to commence by May 15, 2025, subject to customary closing conditions, including securing at least $40.0 million in cash.
May 1, 2025, 12:00 AM
Kronos Bio Reports Q4 and Full-Year 2024 Results
KRON
Earnings
- Kronos Bio, Inc. reported its Q4 2024 financial results on March 18, 2025, with a net loss of $25.8 million and a full-year net loss of $86.1 million, corresponding to $0.43 and $1.43 per share respectively.
- The company recorded cash, cash equivalents, and investments of $112.4 million as of December 31, 2024, and provided detailed breakdowns of R&D, G&A, and impairment charges in the quarter and full year.
- The press release also highlighted significant non-cash expenses, including stock-based compensation and restructuring charges, underscoring the company’s rigorous expense management during fiscal 2024.
Mar 18, 2025, 12:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more